Core Insights - On November 5, Weigao Blood Purification experienced a decline of 3.98% in stock price, with a trading volume of 559 million yuan [1] - The company recorded a financing purchase amount of 107 million yuan and a net financing purchase of approximately 60.05 million yuan on the same day [1][2] - As of November 5, the total financing and securities lending balance for Weigao Blood Purification was 267 million yuan, representing 15.66% of its circulating market value [2] Financial Performance - For the period from January to September 2025, Weigao Blood Purification achieved a revenue of 2.736 billion yuan, reflecting a year-on-year growth of 3.45% [2] - The net profit attributable to the parent company for the same period was 341 million yuan, marking a year-on-year increase of 7.92% [2] Shareholder Information - As of September 30, the number of shareholders for Weigao Blood Purification was 24,800, a decrease of 20.95% compared to the previous period [2] - The average number of circulating shares per shareholder increased by 26.51% to 1,535 shares [2] Dividend Information - Since its A-share listing, Weigao Blood Purification has distributed a total of 65.8213 million yuan in dividends [3]
威高血净11月5日获融资买入1.07亿元，融资余额2.67亿元